prof. dr. E.G.E. (Elisabeth) de Vries
Member of the Royal Netherlands Academy of Arts and Sciences (KNAW) since 2002; Member supervisory board of the Netherlands Comprehensive Cancer organisation (IKNL), 2015-present; Member European Society of Medical Oncology (ESMO)-Magnitude of Clinical Benefit Scale (MCBS) working group, 2013-present; Member and since 2017 chair ESMO Cancer Medicines Working Group, 2015-present; Co-Chair RECIST committee, 2009-present; Member and since 2021 chair scientific advisory board, 2018-present; Chair WHO Essential Medicines List Cancer Working Group, 2021; Member Expert panel for selection of Essential Medicine List WHO, 2019 and 2021; Member Strategic Advisory Board (SAB) National Cancer Imaging Translational Accelerator (NCITA) Award, 2019-current. Member ESMO guideline committee, steering committee member, 2015-2019; Member Governing Body European Academy of Cancer Sciences, 2010-2018; Member Cancer Research UK’s Centre Network Accelerator Award (CNAA) panel, 2016-current; Chair Grant Selection Exploration Committee Dutch Cancer Society, 2016-2020; Member domain jury ‘Levens-, Aard- en Milieuwetenschappen’, Royal Netherlands Academy of Arts and Sciences (KNAW) , 2014-2020. PI: Alpe d’HuZes grant IMPACT, Dutch Cancer Society grant POINTING, Dutch Cancer Society grant N-CIA, IMI TRISTAN, IMI Immune-Image. In the past 3 years Institutional Financial Support for Advisory Boards of NSABP, Daiichi Sankyo, and Crescendo Biologics; Institutional Financial Support for contracted research or clinical trials of Amgen, Bayer, Crescendo Biologics, CytomX Therapeutics, G1 Therapeutics, Roche, Genentech, Servier, Synthon, Regeneron.
|Last modified:||25 June 2022 01.26 a.m.|